---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-329528"
form_type: "8-K"
ticker: "SPTX"
cik: "0002042347"
company_name: "Seaport Therapeutics, Inc."
filed_at: "2026-08-03T11:03:03+00:00"
generated_at: "2026-08-03T11:05:19.925041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Seaport Therapeutics Q2 net loss $62.6M; cash $427.3M; GlyphAllo Phase 2b on track for 1H 2027

## Summary
- Net loss of $62.6M for Q2 2026 vs $15.1M in Q2 2025; increase driven by one-time IPO-related stock-based compensation.
- Cash, cash equivalents, and investments of $427.3M as of June 30, 2026, expected to fund operations into 2029.
- Phase 2b BUOY-1 trial of GlyphAllo in MDD on track; topline data expected in 1H 2027.
- Positive Phase 1 data for GlyphAgo: 6.8-fold bioavailability increase vs unmodified agomelatine; Phase 2a in GAD planned for 2H 2026.
- Completed upsized IPO in May 2026 raising $260M gross proceeds; Sharon Mates appointed to board.

## SEC filing metadata
- accession: 0001193125-26-329528
- form_type: 8-K
- ticker: SPTX
- cik: 0002042347
- company_name: Seaport Therapeutics, Inc.
- filed_at: 2026-08-03T11:03:03+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/0001193125-26-329528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-329528
- JSON: https://secwatch.observer/filing/0001193125-26-329528.json
- Plain text: https://secwatch.observer/filing/0001193125-26-329528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.